[Myocarditis and inflammatory cardiomyopathy--current treatment options]

Area of Science:

• Cardiology
• Immunology
• Pathology

Context:

• Myocarditis is a heart inflammation often triggered by autoimmune issues or viral infections.
• While non-invasive tests have improved, endomyocardial biopsy (EMB) remains the definitive diagnostic method for myocarditis.
• Persistent inflammation or unresolved infections necessitate EMB for accurate diagnosis and treatment planning.

Purpose:

• To highlight the indispensable role of endomyocardial biopsies (EMBs) in diagnosing myocarditis and inflammatory cardiomyopathy.
• To emphasize EMB's utility in identifying specific causes and disease status when non-invasive methods are insufficient.
• To underscore the importance of EMB in guiding targeted antiviral or anti-inflammatory treatments.

Summary:

• Endomyocardial biopsy (EMB) is the gold standard for diagnosing myocarditis and inflammatory cardiomyopathy, especially when autoimmune processes or viral infections trigger persistent inflammation.
• EMB provides critical etiological and prognostic information, enabling tailored antiviral or anti-inflammatory therapies beyond standard heart failure management.
• Conditions like giant cell myocarditis and cardiac sarcoidosis significantly benefit from EMB-guided anti-inflammatory treatment in acute and chronic phases.

Impact:

• EMB facilitates precise diagnosis and targeted therapy initiation for myocarditis, potentially improving patient outcomes.
• This diagnostic approach is vital for managing complex inflammatory cardiomyopathies, including those requiring immunosuppression.
• While current evidence suggests promise for specific therapies, further large-scale randomized trials are needed to confirm their impact on clinical endpoints.